Chelatec
Private Company
Funding information not available
Overview
Chelatec is a specialized preclinical contract research organization (CRO) with over two decades of expertise in radioactive tracer technology. It serves as a critical partner for pharma and biotech companies, offering end-to-end services from custom radiolabeling strategy through in vitro and in vivo pharmacokinetic studies, with a strong focus on novel biologic entities and radiopharmaceuticals. The company has established a strong reputation for reliability and scientific rigor, evidenced by a global client base, a high rate of repeat business, and a successful track record of over 650 completed projects. Its integrated facilities, including dedicated hot labs and animal housing, allow it to manage complex radioactive studies under a single roof.
Technology Platform
Integrated platform for radioactive labeling (iodination, tritiation, chelator-based) of biologics and small molecules, coupled with in vitro assays and in vivo DMPK/ADME studies in dedicated hot labs, cell culture, and animal facilities.
Opportunities
Risk Factors
Competitive Landscape
Chelatec competes within the niche segment of preclinical CROs specializing in radiotracer studies. Competitors include the radiolabeling service units of large, full-service CROs (e.g., Labcorp, Charles River) and smaller, focused CROs similar to itself. Its differentiation lies in its deep, 20-year focus on radiolabeling, integrated facilities, and specific expertise in biologics and therapeutic radiopharmaceuticals.